Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
-
Published:2024-01
Issue:1
Volume:85
Page:97-98
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Rosellini Matteo,
Tassinari Elisa,
Marchetti Andrea,
Mollica Veronica,
Massari FrancescoORCID
Reference10 articles.
1. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial;Pal;Lancet,2023
2. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2023
3. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer;Yearley;Clin Cancer Res,2017
4. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol,2016
5. CaboPoint: interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC);Albiges;J Clin Oncol,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献